Lexicon Pharmaceuticals (LXRX) Shares Outstanding (Weighted Average) (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $400.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $400.2 million, up 10.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $400.2 million (up 10.54% YoY), and the FY2025 annual result was $363.1 million, up 13.44% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $400.2 million in Q1 2026 per LXRX's latest filing, from $363.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $400.2 million in Q1 2026 and troughed at $224128.0 in Q4 2022.
• A 5-year average of $249.5 million and a median of $245.4 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) slumped 99.85% in 2022, then jumped 98562.37% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $224128.0 in 2022, then jumped by 98562.37% to $221.1 million in 2023, then surged by 44.73% to $320.0 million in 2024, then climbed by 13.44% to $363.1 million in 2025, then increased by 10.24% to $400.2 million in 2026.
• Business Quant data shows LXRX's Shares Outstanding (Weighted Average) at $400.2 million in Q1 2026, $363.1 million in Q4 2025, and $363.4 million in Q3 2025.